- Home
- OMH vs NXTC Comparison
OMH vs NXTC Comparison
Compare OMH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- NXTC
- Stock Information
- Founded
- OMH 2015
- NXTC 2015
- Country
- OMH Singapore
- NXTC United States
- Employees
- OMH N/A
- NXTC N/A
- Industry
- OMH Real Estate
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- NXTC Health Care
- Exchange
- OMH Nasdaq
- NXTC Nasdaq
- Market Cap
- OMH 13.6M
- NXTC 13.9M
- IPO Year
- OMH 2023
- NXTC 2019
- Fundamental
- Price
- OMH $1.47
- NXTC $0.40
- Analyst Decision
- OMH Hold
- NXTC Strong Buy
- Analyst Count
- OMH 1
- NXTC 2
- Target Price
- OMH N/A
- NXTC $3.50
- AVG Volume (30 Days)
- OMH 179.3K
- NXTC 340.4K
- Earning Date
- OMH 07-18-2025
- NXTC 07-31-2025
- Dividend Yield
- OMH N/A
- NXTC N/A
- EPS Growth
- OMH N/A
- NXTC N/A
- EPS
- OMH N/A
- NXTC N/A
- Revenue
- OMH $7,976,578.00
- NXTC N/A
- Revenue This Year
- OMH $28.40
- NXTC N/A
- Revenue Next Year
- OMH $23.07
- NXTC N/A
- P/E Ratio
- OMH N/A
- NXTC N/A
- Revenue Growth
- OMH 117.53
- NXTC N/A
- 52 Week Low
- OMH $0.59
- NXTC $0.22
- 52 Week High
- OMH $6.20
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- OMH 45.64
- NXTC 37.68
- Support Level
- OMH $1.32
- NXTC $0.42
- Resistance Level
- OMH $1.60
- NXTC $0.50
- Average True Range (ATR)
- OMH 0.10
- NXTC 0.04
- MACD
- OMH 0.03
- NXTC -0.01
- Stochastic Oscillator
- OMH 53.07
- NXTC 4.17
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.